Gaining Stereoselectivity in Asymmetric Synthesis - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Gaining Stereoselectivity in Asymmetric Synthesis
Researchers use inorganic catalysts as an alternative to biocatalysts in the selective conversion of sugars to produce chiral building blocks.


Pharmaceutical Technology
Volume 37, Issue 2

References

1. Y. Román-Leshkov, "Sn-Beta Zeolites with Borate Salts Catalyze the Epimerization of Carbohydrates via an Intramolecular Carbon Shift," Nature Comnun., online, DOI:10.1038/ncomms2122, Oct. 9, 2012.

2. I. Shiina, J. Med Chem. 56 (1), 150–159 (2013).

3. J. Zhou, "Organocatalytic Asymmetric Synthesis of 3,3-Disubstituted Oxindoles Featuring Two Heteroatoms at C3 position," Chem. Commun., online, DOI: 10.1039/C3CC38819K, Jan. 23, 2013.

4. A.D. Lim, J.A. Codelli, and S.E. Reisman, "Catalytic Asymmetric Synthesis of Highly Substituted Pyrrolizidines," Chem. Sci., online, DOI: 10.1039/C2SC21617E, Nov. 13, 2012.

5. M.J. Abrahamson, Angew. Chem., Int. Ed. Engl., 51 (16), 3969–3972 (2012).

6. G. Sahoo, Angew. Chem., Int. Ed. Engl. 51 (52), 13144–13148 (2012).

7. W. Sommer and D. Weibel, Aldrich ChemFiles 8.2 (56) (2008).

8. D.H. Paull, J. Am. Chem. Soc., 134 (27), 11128–11131 (2012).

9. C. Drahl, Chem. & Eng. News 90 (28), 29 (2012).

Patricia Van Arnum is executive editor of Pharmaceutical Technology, 485 Route One South, Bldg F, First Floor, Iselin, NJ 08830 tel. 732.346.3072,
twitter@PharmTechVArnum


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here